Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 42, Issue 3, 2003, Pages 345-354

  Maestu, I ^a   Gomez Aldaravi L ^b   Torregrosa, M D ^c   Camps, C ^d   Llorca, C ^e   Bosch, C ^f   Gomez J ^g   Giner, V ^e   Oltra, A ^a   Albert, A ^d  

^a HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c HOSPITAL LLUÍS ALCANYÍS   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e Hospital General   (Spain)

^f HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Carboplatin; Comorbidity; Elderly; Gemcitabine; Lung cancer; Symptom

Indexed keywords

CARBOPLATIN; GEMCITABINE;

AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG TOLERABILITY; EVALUATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 10744229871     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00356-8     Document Type: Article

References (51)

1. Osterlind K, Sorensen JB. Prognostic factors. In: Aisner J, Arriagada R, Green MR, et al., editors. Comprehensive textbook of thoracic oncology. Baltimore, MD: Williams & Wilkins; 1996. p. 319-35.
2. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A. Jr., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341:1999;2061-2067.
3. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H.H. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1821-1826.
4. Abratt R.P., Bezwoda W.R., Falkson G., Goedhals L., Hacking D., Rugg T.A. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1525-1540.
5. Thatcher N., Jayson G., Bradley B., Ranson M., Anderson H. Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. Semin. Oncol. 24(Suppl 8):1997;S8-S16.
6. Steward W.P., Dunlop D.J., Dabouis G., Lacroix H., Talbot D. Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results. Semin. Oncol. 23:1996;43-47.
7. Abratt R.P., Bezwoda W.R., Goedhals L., Hacking D.J. Weekly gemcitabine with monthly cisplatin effective chemotherapy for advanced non-small cell lung cancer. J. Clin. Oncol. 15:1997;744-749.
8. Crinó L., Scagliotli G., Marangolo M., Figoli F., Clerici M., De Marinis F.et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a phase II study. J. Clin. Oncol. 15:1997;297-303.
9. Einhorn L. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study. Semin. Oncol. 24(Suppl 8):1997;24-26.
10. Antón A., Carrato A., Gonzalez-Larriba J.L. Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 15:1996;A-1134.
11. Shepherd F.A., Cormier Y., Burkers R., Evans W.K., Goss G., Klimo P.et al. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Semin. Oncol. 24(Suppl 8):1997;27-30.
12. Castellano D, Lianes P, Guerra JA, Gómez-Martín C, Paz-Ares L, Cortés-Funes H. Phase II study of gemcitabine and cisplatin every 3 weeks in patients with non-small cell lung cancer. In: Proceedings of the Eighth World Conference on Lung Cancer. Dublin, 10-15 August 1997, p. A-100.
13. Cardenal F., López-Cabrerizo M.P., Antón A., Alberola V., Massuti B., Carrato A.et al. Randomized phase III study of gemcitabine- cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell-lung cancer. J. Clin. Oncol. 17:1999;12-18.
14. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J.et al. Comparison of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). N. Engl. J. Med. 346:2002;92-98.
15. Gatzemeier U., Heckmayr M., Hossfeld D.K., Zschaber R., Achterrath W., Lenaz L. Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer. Cancer Chemother. Pharmacol. 26:1990;369-372.
16. Shibata K., Nakatsumi Y., Kasahara K., Bando T., Fujimura M., Matsuda T. Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patient with lung cancer. J. Cancer Res. Clin. Oncol. 122:1996;437-442.
17. Carmichael J., Allerheiligen S., Walling J. A Phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin. Oncol. 23(5):1996;55-59.
18. Carmichael J, Langley R, Osbourne L, Andrews L, Woll PJ, Stickland JE. A phase I study to investigate alternate sequencing of the combination gemcitabine followed by carboplatin in NSCLC, ECCO 9. Hamburg, Germany, 14-18 September 1997.
19. Langer C.J., Gandara D.R., Calvert P., Edelman M.J., Ozols R.F. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. Semin. Oncol. 26(Suppl 4):1999;12-18.
20. Martinez J., Panizo A., Alonso M.A., Muñoz J., De Cos Sanchez J., Sampedro J.R.et al. Gemcitabine plus carboplatin in advanced non-small cell lung cancer (NSCLC): a phase I trial. Proc. Am. Soc. Clin. Oncol. 17(494a):1998;A-1903.
21. Gajra A., Mehdi S.A., Kirshner J., Graziano S.L. A phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma (NSCLC). Proc. Am. Soc. Clin. Oncol. 19(538a):2000;A-2119.
22. Thomas P., Robinet G., Lena H., Vernejoux J., Kleisbauer J. A phase I dose escalation study of carboplatin (C) and gemcitabine (G) for previously untreated stage IV non-small cell lung cancer (NSCLC). GFPC study 97-01. Proc. Am. Soc. Clin. Oncol. 19(522a):2000;A-2051.
23. Iaffaioli R.V., Tortoriello A., Facchini G., Caponigro F., Gentile M., Marzano N.et al. Phase I/II of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J. Clin. Oncol. 17:1999;921-926.
24. Carrato A, Alberola V, Massuti B, Galán A, Sánchez JJ, García-Gómez J, et al. Combination of gemcitabine (Gem) and carboplatin (Carbo) as first line treatment in non-small cell lung cancer. Ann Oncol 1998;9 (89 Suppl 4):A-431.
25. Ng E.W., Sandler A.B., Einhorn L.H. A phase II study of carboplatin plus gemcitabine in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;468. [A-1801].
26. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Baxall F.E.et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 17:1989;1748-1756.
27. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 16:1976;31-41.
28. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
29. Hollen P.J., Gralla R.J., Kris M., Potanovich L.M. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur. J. Cancer. 29a(Suppl 1):1993;51-58.
30. Gridelli C., Perrone F., Gallo C., De Marinis F., Ianniello G., Cigolan S.et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur. J. Cancer. 33:1997;392-397.
31. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A New method of classifying prognostic comorbidity in longitudinal studios: development and validation. J. Chron. Dis. 40(5):1987;373-383.
32. Frasci G. Chemotherapy of lung cancer in the elderly. Critical reviews in oncology/hematology. 41:2002;349-361.
33. Balducci L., Extermann M. Cancer and ageing: an evolving panorama. Hematol. Oncol. Clin. N. Am. 14:2000;1-16.
34. Yancik R., Ries L.A.G. Cancer in the aged: an epidemiologic perspective on treatment issues. Cancer. 68(11 Suppl):1991;2502-2510.
35. Duthie E. Physiology of ageing: relevance to symptom percepcions and treatment tolerance. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. London: Harwood; 1998. 247-62.
36. Balducci L., Corcoran M.B. Antineoplastic chemotherapy of the older cancer patient. Hematol. Oncol. Clin. N. Am. 14:2000;193-212.
37. Cova D, Beretta G, Balducci L. Cancer chemotherapy in the older patient. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. London: Harwood; 1998. 429-42.
38. Léger F., Séronic-Vivien S., Makdessi J., Lochon I., Delord J.P., Sarda C.et al. Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study. Eur. J. Cancer. 38:2002;52-56.
39. Ramon J.M., Subirá C. Prevalence of malnutrition in elderly Spanish population. Med. Clin. 117:2001;766-770.
40. Misra D.P., Loudon J.M., Staddon G.E. Albumin metabolism in elderly patients. J. Gerontol. 30:1975;304-306.
41. Balducci L., Beghé C. Pharmacology of chemotherapy in the older cancer patients. Cancer Control. 6:1999;466-470.
42. Shepherd F.A., Abratt R.P., Anderson H., Gatzemeier U., Anglin G., Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin. Oncol. 24(2 Suppl 7):1997;750-755.
43. Martin C., Ardizzoni A., Rosso R. Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Ageing Clin. Exp. Res. 9:1997;297-303.
44. Sederholm C. Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc. Am. Soc. Clin. Oncol. 21:2002;A-1162.
45. Rocha Lima C.M., Herndon J.E., Kosty M., Clamn G., Green M.R. Therapy choices among older patients with lung carcinoma. An evaluation of two trials of the cancer and leukemia group B. Cancer. 94:2002;181-187.
46. Langer C.J., Manola J., Bernardo P., Kugler J.W., Bonomi P., Cella D. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592. J. Natl. Cancer Inst. 94(3):2002;173-181.
47. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol. 16:1998;1582-1587.
48. Yanagihara R.H., Beck M. Low dose carboplatin (C) and gemcitabine (G ) in advanced non-small cell lung cancer (NSCLC): an active combination with low toxicity. Proc. Am. Soc. Clin. Oncol. 19(527a):2000;A-2072.
49. Ricci S., Antonuzzo A., Galli L., Tibaldi C., Bertuccelli M., Lopes Pegna A.et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer. 27(2):2000;75-80.
50. Repetto L., Fratino L., Audisio R.A., Venturino A., Gianni W., Vercelli M.et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian group for geriatric oncology study. J. Clin. Oncol. 20(2):2002;494-502.
51. Lilenbaum R.C., Herndon J., List M., Desch C., Watson D., Holland J.et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc. Am. Soc. Clin. Oncol. 21:2002;A-2.